MARKET

RNAM

RNAM

Avidity Biosciences, Inc.
NASDAQ
72.82
+0.02
+0.03%
Suspension 18:34 02/26 EST
OPEN
72.75
PREV CLOSE
72.80
HIGH
73.04
LOW
72.75
VOLUME
16.84M
TURNOVER
--
52 WEEK HIGH
73.06
52 WEEK LOW
21.51
MARKET CAP
11.27B
P/E (TTM)
-14.6475
1D
5D
1M
3M
1Y
5Y
1D
NASDAQ TRADE HALT <RNAM.O> TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Reuters · 6h ago
Avidity Biosciences Inc. Held Special Stockholder Meeting
Reuters · 9h ago
Avidity Biosciences to Present at 2026 MDA Clinical & Scientific Conference
Reuters · 10h ago
Avidity Biosciences Advances Toward Novartis Merger Completion
TipRanks · 3d ago
Avidity Biosciences Delays Shareholder Meeting Until Feb. 26
Reuters · 3d ago
Weekly Report: what happened at RNA last week (0216-0220)?
Weekly Report · 3d ago
NEJM Publishes Phase 1/2 MARINA Trial Results for Avidity’s Del-Desiran in DM1
Reuters · 02/18 22:00
THE NEW ENGLAND JOURNAL OF MEDICINE PUBLISHES RESULTS FROM PHASE 1/2 MARINA® TRIAL OF DELPACIBART ETEDESIRAN (DEL-DESIRAN) FOR TREATMENT OF MYOTONIC DYSTROPHY TYPE 1
Reuters · 02/18 22:00
More
About RNAM
Avidity Biosciences, Inc. is a biopharmaceutical company. The Company is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). The AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Its advancing and expanding pipeline has three programs in clinical development. The Del-desiran is designed to treat people with myotonic dystrophy type 1 (DM1) and is in the global Phase III HARBOR trial and in the ongoing MARINA-OLE trial in people with DM1. The Delpacibart braxlosiran is the first investigational therapy designed to directly target DUX4 in people living with facioscapulohumeral muscular dystrophy (FSHD). The Del-zota is designed for people with Duchenne muscular dystrophy (DMD) and is in development with the Phase II EXPLORE44 open-label extension (OLE) study.

Webull offers Avidity Biosciences Inc stock information, including NASDAQ: RNAM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RNAM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RNAM stock methods without spending real money on the virtual paper trading platform.